Literature DB >> 15816605

The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia.

Jörgen Wenner1, Thomas Zilling, Anna Bladström, Thor A Alvegård.   

Abstract

OBJECTIVE: To study the effects of hospital operation volume on hospital mortality and 5-year survival in patients treated with resection for carcinoma of the oesophagus and gastric cardia.
INTRODUCTION: Surgery due to tumours of the oesophagus and gastric cardia is probably associated with the highest postoperative morbidity and mortality of all elective surgical procedures. Concentration to high-volume centres has been suggested to improve the outcome.
MATERIALS AND METHODS: Between 1987 and 1996, all patients with squamous cell carcinoma or adenocarcinoma of the oesophagus or gastric cardia were identified from the Swedish Cancer Registry and the Swedish Hospital Discharge Registry. The study population was assessed according to patients operated at hospitals with a low (L-V), intermediate (I-V) or high operation volume (H-V), defined as <5 resections/year, 5-15 resections/year and >15 resections/year, respectively. We analyzed hospital mortality and 5-year survival.
RESULTS: During the study period, 1429 patients were treated with resection for carcinoma of the oesophagus (n=665) or the gastric cardia (n = 764). A total of 74 hospitals were registered with at least one surgical resection, of which 90% performed <5 resections/year. The distribution of gender and age was comparable in the three groups. Hospital mortality was 10.4, 6.3 and 3.5% in the L-V, I-V and H-V groups, respectively. Overall 5-year survival was 17% (L-V), 19% (I-V) and 22% (H-V). Multivariate analysis showed an improved long-term survival for patients operated at H-V compared to L-V hospitals (p=0.02).
CONCLUSION: This study supports an inverse relationship between hospital volume and hospital mortality after surgical tumour resection of the oesophagus or gastric cardia. Overall 5-year survival was significantly higher at high-volume hospitals compared to low-volume centres. We believe that concentrating these patients in high-volume hospitals is necessary to achieve high quality surgical treatment and to facilitate research aiming to improve prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 15816605

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

2.  The positive impact of surgeon specialization on survival for gastric cancer patients after surgery with curative intent.

Authors:  Yuexiang Liang; Liangliang Wu; Xiaona Wang; Xuewei Ding; Han Liang
Journal:  Gastric Cancer       Date:  2014-10-15       Impact factor: 7.370

3.  Surgery for oesophageal cancer at Galway University Hospital 1993-2008.

Authors:  K H Chang; O J McAnena; M J Smith; R R Salman; M F Khan; D Lowe
Journal:  Ir J Med Sci       Date:  2010-09-17       Impact factor: 1.568

4.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

5.  Are there regional differences in gynecologic cancer outcomes in the context of a single-payer, publicly-funded health care system? A population-based study.

Authors:  Janice S Kwon; Mark S Carey; E Francis Cook; Feng Qiu; Lawrence F Paszat
Journal:  Can J Public Health       Date:  2008 May-Jun

6.  Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma.

Authors:  Deirdre P Cronin-Fenton; Margaret M Mooney; Limin X Clegg; Linda C Harlan
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

7.  Surgical factors influencing outcomes in patients resected for cancer of the esophagus or gastric cardia.

Authors:  Martin Sundelöf; Jesper Lagergren; Weimin Ye
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

8.  Re-organisation of oesophago-gastric cancer care in England: progress and remaining challenges.

Authors:  Thomas R Palser; David A Cromwell; Richard H Hardwick; Stuart A Riley; Kimberley Greenaway; William Allum; Jan Hp van der Meulen
Journal:  BMC Health Serv Res       Date:  2009-11-12       Impact factor: 2.655

9.  Prognostic factors influencing the survival of patients with carcinoma of the gastric cardia receiving preoperative interventional embolization chemotherapy.

Authors:  Hai-Li Cao; Shu-Qiang Jin; Kai-Bing Wang; Bin Bai
Journal:  Oncotarget       Date:  2017-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.